Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?

A Conversation with an MPN Specialist: Polycythemia Vera

Why is Hydroxyurea First Line Therapy in the US for Essential Thrombocythemia?

What are the common side effects of JAK2 inhibitors? #myelofibrosis

Living with A Rare Blood Cancer, Polycythemia Vera

Essential Thrombocythemia Explained: Causes, Diagnosis & Prognosis

Moving Beyond Hydroxyurea for Polycythemia Vera

What are the unmet needs in the management of myelofibrosis-related anemia?

Blood Cancer Treatment For Polycythemia Vera

How might extended-release formulations of ruxolitinib benefit patients with MF?

How Do I Know If Hydroxyurea is Not Right for Me?

Polycythemia vera: When to move from hydroxyurea to second-line therapy

What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?

The evolving treatment landscape for patients with polycythemia vera

Медицинские истории — Болезнь Кушинга: история Алиссы

Polycythemia & Coagulation Disorders (Hemophilia, ITP, HIT, DIC) - Medical-Surgical | @LevelUpRN

I have cancer (Neuroendocrine tumour)

Dr. John Mascarenhas, MD - PV Moving Beyond Hydroxyurea

How Long Should Patients Take Jakafi® (ruxolitinib)?

Determining when to switch from hydroxyurea to interferon-based therapy in patients with PV